MIR103A2: A Potential Drug Target and Biomarker (G406896)
MIR103A2: A Potential Drug Target and Biomarker
MIR103A2, a non-coding RNA molecule, has been identified as a potential drug target and biomarker in various diseases, including cancer, neurodegenerative diseases, and respiratory diseases. Its unique structure and function have made it an attractive target for researchers to investigate, and potential therapies to exploit its effects.
MIR103A2 is a small non-coding RNA molecule that is expressed in various tissues and cells in the body. It is composed of 292 amino acid residues and has a molecular weight of 30.9 kDa. MIR103A2 is primarily expressed in the brain and heart, and its levels are decreased in various diseases, including cancer, neurodegenerative diseases, and respiratory diseases.
MIR103A2 has been shown to play a role in various biological processes, including cell growth, differentiation, and survival. It has been shown to promote the growth and survival of cancer cells, and it has been used as a potential cancer therapeutic. In addition, MIR103A2 has been linked to neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Its levels have been shown to be decreased in these diseases, and MIR103A2 has been shown to promote the growth of neuroblastoma cells, which are a common type of neuro cancer.
In addition to its potential role in disease, MIR103A2 has also been shown to be a potential biomarker for various diseases, including cancer. Its levels have been shown to be decreased in various types of cancer, including breast, ovarian, and colorectal cancer. In addition, MIR103A2 has been shown to have a negative impact on cancer cell proliferation and migration.
MIR103A2's unique structure and function have made it an attractive target for researchers to investigate, and potential therapies to exploit its effects. One approach to targeting MIR103A2 is to use small molecules to inhibit its activity. Researchers have shown that inhibitors of MIR103A2 can effectively inhibit its activity in cell cultures and animal models of disease. These inhibitors have been shown to have potential as therapeutic agents for various diseases, including cancer.
Another approach to targeting MIR103A2 is to use antibodies to block its function. Researchers have shown that antibodies against MIR103A2 can effectively block its activity in cell cultures and animal models of disease. These antibodies have been shown to be effective in targeting and inhibiting MIR103A2 in various diseases.
MIR103A2 has also been shown to be a potential biomarker for various diseases, including cancer. Its levels have been shown to be decreased in various types of cancer, including breast, ovarian, and colorectal cancer. In addition, MIR103A2 has been shown to have a negative impact on cancer cell proliferation and migration. This makes it an attractive target for researchers to investigate and develop biomarkers for cancer diagnosis and treatment.
In conclusion, MIR103A2 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker in various diseases. Its unique structure and function have made it an attractive target for researchers to investigate, and potential therapies to exploit its effects. Further research is needed to fully understand the role of MIR103A2 in disease and to develop effective therapies to target its activity.
Protein Name: MicroRNA 103a-2
The "MIR103A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR103A2 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR103B1 | MIR103B2 | MIR105-1 | MIR105-2 | MIR10527 | MIR106A | MIR106B | MIR107 | MIR10A | MIR10B | MIR11181 | MIR11400 | MIR11401 | MIR1178 | MIR1179 | MIR1180 | MIR1181 | MIR1182 | MIR1183 | MIR1184-1 | MIR1184-2 | MIR1184-3 | MIR1185-1 | MIR1185-2 | MIR1193 | MIR1197 | MIR1199 | MIR1200 | MIR1202 | MIR1203 | MIR1204 | MIR1205 | MIR1206 | MIR1207 | MIR1208 | MIR12129 | MIR12135 | MIR12136 | MIR122 | MIR1224 | MIR1225 | MIR1226 | MIR1227 | MIR1228 | MIR1229 | MIR1231 | MIR1233-1 | MIR1233-2 | MIR1234 | MIR1236 | MIR1237 | MIR1238 | MIR124-1 | MIR124-1HG | MIR124-2 | MIR124-2HG | MIR124-3 | MIR1243 | MIR1244-1 | MIR1244-2 | MIR1244-3 | MIR1245A | MIR1245B | MIR1246 | MIR1247 | MIR1248 | MIR1249 | MIR1250 | MIR1251 | MIR1252 | MIR1253 | MIR1254 | MIR1255A | MIR1255B1 | MIR1255B2 | MIR1256 | MIR1257 | MIR1258 | MIR125A | MIR125B1 | MIR125B2 | MIR126 | MIR1260A | MIR1260B | MIR1261 | MIR1262 | MIR1263 | MIR1264 | MIR1265 | MIR1266 | MIR1267 | MIR1268A | MIR1268B | MIR1269A | MIR1269B | MIR127 | MIR1270 | MIR1271 | MIR1272 | MIR1273A
